Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 7, Issue 6, 2011, Pages 841-849

  Réjiba, Soukaina ^a   Reddy, L Harivardhan ^b   Bigand, Christelle ^a   Parmentier, Céline ^a   Couvreur, Patrick ^b   Hajri, Amor ^c  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Chemotherapy; Gemcitabine; Gemcitabine squalene; Nanoparticles; Pancreatic cancer

Indexed keywords

ANTI-PROLIFERATIVE; ANTI-TUMOR EFFICACY; APOPTOSIS ASSAYS; BASIC SCIENCE; CELL VIABILITY; CHEMORESISTANCE; CYTOTOXIC EFFECTS; GEMCITABINE; GEMCITABINE-SQUALENE; IN-VIVO; ORTHOTOPIC; PANCREATIC ADENOCARCINOMA; PANCREATIC CANCERS; PANCREATIC TUMORS; SURVIVAL TIME; THERAPEUTIC FAILURE; TUMOR CELL INVASION; TUMOR CELLS; TUMOR GROWTH;

CELL DEATH; CHEMOTHERAPY; CYTOTOXICITY; DISEASES; MEDICAL NANOTECHNOLOGY; NANOPARTICLES; TUMORS;

DRUG PRODUCTS;

4 N TRIS NOR SQUALENOYL GEMCITABINE; GEMCITABINE; KI 67 ANTIGEN; NANOPARTICLE; SQUALENE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INVASION; CANCER SURVIVAL; CELL INVASION; CELL VIABILITY; CHEMOSENSITIVITY; CYTOTOXICITY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NANOMEDICINE; NONHUMAN; PANCREAS ADENOCARCINOMA;

ADENOCARCINOMA; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; CELL LINE; CELL LINE, TUMOR; DEOXYCYTIDINE; FEMALE; HUMANS; MICE; MICE, NUDE; NANOMEDICINE; NANOPARTICLES; PANCREAS; PANCREATIC NEOPLASMS; SQUALENE;

MUS;

EID: 82255175232     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2011.02.012     Document Type: Article

References (31)

1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M Cancer statistics. CA Cancer J Clin 2001, 51:15-36.
2. Janes RH, Niederhuber JE, Chmiel JS, Winchester DP, Ocwieja KC, Karnell JH, et al. Pattern of care for pancreatic cancer: results of a survey by the omission on cancer. Ann Surg 1996, 223:261-272.
3. Yeo TP, Hruban RH, Leach SD, Wilentz RE, Sohn TA, Kern SE, et al. Pancreatic cancer. Curr Probl Cancer 2002, 26:176-275.
4. Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreatic cancer: a randomized-trial. J Clin Oncol 1997, 15:2403-2413.
5. Burris H, Storniolo AM Assessing clinical benefit in the treatment of pancreas cancer: gemcitabine compared to 5-fluorouracil. Eur J Cancer 1997, 33(Suppl):18-22.
6. Rothenberg ML, Moore MJ, Cripps MC, Andersen JS, Portenoy RK, Burris HA, et al. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 1996, 7:347-353.
7. Abratt RP, Bezwoda WR, Falkson G, Goedhals L, Hacking D, Rugg TA Efficacy and safety profile of gemcitabine in non-small cell lung cancer. phase II study. J Clin Oncol 1994, 12:1535-1540.
8. Lund B, Hansen OP, Theilade K, Hansen M, Neijit JP Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst 1994, 86:1530-1533.
9. Braakhuis BJ, Ruiz van Haperen VW, Boven E, Veerman G, Peters GJ Schedule dependent antitumor effect of gemcitabine in vivo model systems. Semin Oncol 1995, 22:42-46.
10. Heinemann V Gemcitabine: progress in the treatment of pancreatic cancer. Oncology 2001, 60:8-18.
11. Clasina LVDW, Judith RK, Andries MB, Willem JPL, Enrique A, Iannnis T, et al. The role of deoxycytidine kinase in gemcitabine cytotoxicity. Adv Exp Med Biol 2006, 486:287-290.
12. Bergman AM, Pinedo HM, Peters G Determinants of resistance to 2',2'-difluorodeoxycytidine (gemcitabine). Drug Resistance Updates 2002, 5:19-33.
13. Réjiba S, Bigand C, Parmentier C, Hajri A Gemcitabine-based chemogene therapy for pancreatic cancer using Ad-dCK::UMK GDEPT and TS/RR siRNA strategies. Neoplasia 2009, 11:637-650.
14. Bergman AM, Eijk PP, Ruiz van Haperen VW, Smid K, Veerman G, Hubeek I, et al. In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant. Cancer Res 2005, 65:9510-9516.
15. Qiu LX, Tang QY, Bai JL, Qian XP, Li RT, Liu BR, et al. Predictive value of thymidylate synthase expression in advanced colorectal cancer patients receiving fluoropyrimidine-based chemotherapy: evidence from 24 studies. Int J Cancer 2008, 15:2384-2389.
16. Kroep JR, Loves WJ, van der Wilt CL, Alvarez E, Talianidis I, Boven E, et al. Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity. Mol Cancer Ther 2002, 1:371-376.
17. Ueno H, Kiyosawa K, Kaniwa N Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy?. Br J Cancer 2007, 97:145-151.
18. Laura IM, Brusa P, Rocco F, Arpicco S, Ceruti M, Cattel L Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs. J Control Release 2004, 100:331-346.
19. Castelli F, Sarpietro MG, Ceruti M, Rocco F, Cattel L Characterization of lipophilic gemcitabine prodrug-liposomal membrane interaction by differential scanning calorimetry. Mol Pharm 2006, 3:737-744.
20. Couvreur P, Stella B, Reddy LH, Hillaireau H, Dubernet C, Dismaele D, et al. Squalenoyl nanomedicines as potential therapeutics. Nano Lett 2006, 6:2544-2548.
21. Couvreur P, Reddy LH, Mangenot S, Poupaert JH, Desmaële D, Lepêtre-Mouelhi S, et al. Discovery of new hexagonal supramolecular nanostructures formed by squalenoylation of an anticancer nucleoside analogue. Small 2008, 4:247-253.
22. Wack S, Rejiba S, Parmentier C, Aprahamian M, Hajri A Telomerase transcriptional targeting of inducible Bax/TRAIL gene therapy improves gemcitabine treatment of pancreatic cancer. Mol Ther 2008, 16:252-260.
23. Reddy LH, Marque PE, Dubernet C, Dubernet C, Moulhi SL, Desmaele D, et al. Preclinical toxicology (subacute and acute) and efficacy of a new squalenoyl gemcitabine anticancer nanomedicine. J Pharmacol Exp Ther 2008, 325:484-490.
24. Venugopal J, Prabhakaran MP, Low S, Choon AT, Zhang YZ, Deepika G, et al. Nanotechnology for nanomedicine and delivery of drugs. Curr Pharm Des 2008, 14:2184-2200.
25. Diehl AJ, Benzeno S Cyclin D1 and pancreatic carcinoma: aproliferative agonist and chemotherapeutic antagonist. Clin Cancer Res 2005, 11:5665-5667.
26. Biliran H, Wang Y, Banerjee S, Xu H, Heng H, Thakur A, et al. Overexpression of cyclin D1 promotes tumor cell growth and confers resistance to cisplatin-mediated apoptosis in an elastase-myc transgene-expressing pancreatic tumor cell line. Clin Cancer Res 2005, 11:6075-6086.
27. Nakano Y, Tanno S, Koizumi K, Nishikawa T, Nakamura K, Minoguchi M, et al. Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells. Br J Cancer 2007, 96:457-463.
28. Mackey JR, Mani RS, Selner M, Mowles D, Young JD, Belt JA, et al. Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res 1998, 58:4349-4357.
29. Bildstein L, Dubernet C, Marsaud V, Chacun H, Nicolas V, Gueutin C, et al. Transmembrane diffusion of gemcitabine by a nanoparticulate squalenoyl prodrug: an original drug delivery pathway. J Control Release 2010, 147:163-170.
30. Bildstein L, Marsaud V, Chacun H, Lepêtre-Mouelhi S, Desmaële D, Couvreur P, et al. Extracellular-protein-enhanced cellular uptake of squalenoyl gemcitabine from nanoassemblies. Soft Matter 2010, 6:5570-5580.
31. Reddy LH, Khoury H, Paci A, Deroussent A, Ferreira H, Dubernet C, et al. Squalenoylation favorably modifies the in vivo pharmacokinetics and biodistribution of gemcitabine in mice. Drug Metab Dispos 2008, 36:1570-1577.